Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...
Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...
Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis • The investigational transcatheter aortic valve implantation (TAVI) system will ...
Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease -- aortic stenosis (AS).
The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.
FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...
system will complement Abbott's Navitorâ„¢ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The investigational system is designed to offer best-in-class heart ...